# Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

Study · id `cardio:ct-nct07091682` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07091682](<https://clinicaltrials.gov/study/NCT07091682>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07091682

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07091682. Allocation not applicable; no masking; primary purpose treatment. Start 2025-02-18 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07091682, source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)
- Started: 2025-02-18 (actual) (ClinicalTrials.gov record NCT07091682, source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07091682, source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)
- Completion: 2031-06 (anticipated) (ClinicalTrials.gov record NCT07091682, source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)
- Countries: Germany; Hungary; Italy; Latvia; Poland; Spain; Switzerland (ClinicalTrials.gov record NCT07091682, source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07091682-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
- Acronym: BIOMAG-LL
- Condition: Coronary Artery Disease
- Condition: Atherosclerosis of Coronary Artery
- Condition: Myocardial Ischemia
- Condition: Ischemic Heart Disease
- Condition: Acute Coronary Syndromes
- Condition: Angina Pectoris
- Intervention (Device): Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

## Provenance

Content hash: 17198d5f16b1753cc02c616c33c7dd82de7193692106cbe002ba250777d183d1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
